Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

- PMLiVE

Takeda to pay $2.4bn to settle Actos cancer suits

Will be one of the largest drug safety settlements in US history

- PMLiVE

Sanofi wins European approval for Lantus follow-up Toujeo

Long-acting insulin is a key part of the company's growth plans

Sanofi reception

Sanofi gains accelerated review for rare disease drug

New pill for Fabry disease could be approved by the FDA before the end of the year

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

Astellas signs up to immuno-oncology deal

Japanese firm the latest pharma company to buy into the next-gen cancer therapy area

Making a difference with mobile health

Sanofi talks to PME about its latest mHealth initiative and tackling the diabetes epidemic

- PMLiVE

Merck files Keytruda for lung cancer

Filed to the FDA as a treatment option for NSCLC patients

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

- PMLiVE

ReNeuron aiming to take second stem cell therapy into clinic

Will test its human retinal progenitor cell for genetic eye disease RP

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links